The U.S. Food and Drug Administration (FDA) acknowledged this week that there is a nationwide shortage of the drug Adderall for attention deficit hyperactivity disorder (ADHD), confirming previous warnings from manufacturers, pharmacists and patients.
Adderall’s largest manufacturer in the United States, Teva Pharmaceuticals Industries, Ltd., said last month that a labor shortage earlier in the year caused production stoppages, but the company anticipated any shortages at the sales level. retail would be resolved within a few weeks.
|TEVA||TEVA INDUSTRIE FARMACEUTICHE LTD.||7.95||-0.26||-3.17%|
But since then, the shortages have spread to other drug companies producing generic versions of the treatment as desperate patients seek alternatives and there are signs that the situation could worsen further.
FDA AUTHORIZES BIVALENT COVID BOOSTERS FOR SMALL CHILDREN
The FDA said in its press release Wednesday that Teva “is experiencing continuous intermittent production delays,” indicating that the outages earlier this year have not yet been resolved.
Last week, an FDA spokesperson told FOX News Digital that the agency was in contact with manufacturers of Adderall-type drugs and monitoring supplies, but stopped short before declaring a shortage.
WALMART, CVS ACHIEVES PURCHASE OF $ 147.5 M WITH WESTERN VIRGINIA
Experts say there are several factors contributing to the shortage, including record prescriptions for mixed amphetamine salts following COVID-19 blockades, a surge in recreational use of the stimulant, and federal government limits banning manufacturers. to increase production when stocks are low.
Despite pleas from patients who rely on the drug to focus but are unable to meet their prescriptions, federal regulators seem reluctant to allow drug manufacturers to increase production to meet demand.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The US Drug Enforcement Administration, which regulates production quotas for controlled substances, told the Wall Street Journal that there is no plan to raise ADHD drug production limits next year. The agency cited concerns about young adults abusing drugs.